Korea Has the World's Highest Demand for Fertility Treatment... "Access Has Improved, but Gaps Remain"
Fertility drug pen coverage expanded nearly 10 years later than in Europe
Coverage expanded to more patients in 2024... pen products covered starting this September
Merck: "Expand early fertility testing... infertility is a race against time"
Merck, a leader in the global fertility treatment market, said Korea's fertility treatment environment "has some catching up to do." Although the share of births resulting from assisted reproductive technology is high, with one in five babies born in Korea arriving through such procedures, it took a long time for National Health Insurance coverage to expand after fertility drugs were approved.
Alexander Steinbach, Global Head of Fertility and Endocrinology at Merck Healthcare and a senior vice president, said at the media seminar “Digital Healthcare-Based Fertility and Growth Treatment Portfolio,” held on November 11 at the Korea Science and Technology Center in Gangnam-gu, Seoul: “Access to fertility treatment in Korea has improved in recent years, but coverage for Pergoveris, one of Merck’s leading fertility treatments, was expanded only two years ago, and the pen product has only just been launched. In Europe, patients have been using this pen for nearly 10 years, so Korea has some catching up to do.”
Alexander Steinbach, Global Head of Fertility and Endocrinology at Merck Healthcare (left), and Christoph Hamann, head of Merck Healthcare Korea, speak at a media seminar held at the Korea Science and Technology Center in Gangnam-gu, Seoul, on the 11th. Photo by Park Jeongyeon
View original imageAccording to Merck, about one in five babies born in Korea is conceived through assisted reproductive technology, such as in vitro fertilization. This is the highest share in the world, with Japan next. Sixty percent of women receiving fertility treatment are aged 35 or older.
Despite demand for fertility treatment, the introduction of the drugs came late. Merck’s Gonal-f, an injection used to induce superovulation, was approved in Europe in 1995 and in the United States in 1997, but was not approved in Korea until 2007. Pergoveris, which combines follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in one product, was first approved in Europe in 2007 and introduced in Korea in 2010. Initially, National Health Insurance coverage for Pergoveris was limited to some patients with severe deficiencies. Coverage was expanded to include patients regardless of the degree of their deficiency in April 2024. The easy-to-use pen product became eligible for coverage starting in September 2026.
Christoph Hamann, Head of Merck Healthcare Korea, said: “When the medication came in glass vials, patients faced much greater inconvenience and burden, as well as more pain from injections. We had seen from experience in other countries that the pen could greatly reduce this burden, so we worked hard to secure coverage.”
Steinbach and Hamann also emphasized that earlier testing is needed to improve fertility treatment in Korea. In a survey of 1,000 women in their 30s conducted by Merck Healthcare Korea in 2026, 75.2% said reproductive health should be managed early, but only 12.5% had taken an anti-Müllerian hormone (AMH) test, which estimates the number of eggs remaining in the ovaries.
Hamann proposed adding AMH testing as an optional item in workplace health checkups, saying: “Because fertility is a race against time, access should be expanded so that people can preserve their fertility at a younger age.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In the long term, Korea may also take part in clinical trials for new fertility drugs. Steinbach said: “If clinical trials begin, we will of course consider Korea’s participation.” Hamann said: “Whenever a clinical trial is planned, we will actively recommend including Korea, especially in trials related to fertility.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.